390 related articles for article (PubMed ID: 30282713)
1. Salinomycin Inhibits Influenza Virus Infection by Disrupting Endosomal Acidification and Viral Matrix Protein 2 Function.
Jang Y; Shin JS; Yoon YS; Go YY; Lee HW; Kwon OS; Park S; Park MS; Kim M
J Virol; 2018 Dec; 92(24):. PubMed ID: 30282713
[TBL] [Abstract][Full Text] [Related]
2. Viral M2 ion channel protein: a promising target for anti-influenza drug discovery.
Moorthy NS; Poongavanam V; Pratheepa V
Mini Rev Med Chem; 2014; 14(10):819-30. PubMed ID: 25342196
[TBL] [Abstract][Full Text] [Related]
3. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
Ilyushina NA; Hoffmann E; Salomon R; Webster RG; Govorkova EA
Antivir Ther; 2007; 12(3):363-70. PubMed ID: 17591026
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of influenza virus replication by plant-derived isoquercetin.
Kim Y; Narayanan S; Chang KO
Antiviral Res; 2010 Nov; 88(2):227-35. PubMed ID: 20826184
[TBL] [Abstract][Full Text] [Related]
5. Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 with
Cáceres CJ; Hu Y; Cárdenas-García S; Wu X; Tan H; Carnaccini S; Gay LC; Geiger G; Ma C; Zhang QY; Rajao D; Perez DR; Wang J
Emerg Microbes Infect; 2021 Dec; 10(1):1832-1848. PubMed ID: 34427541
[TBL] [Abstract][Full Text] [Related]
6. Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
Baranovich T; Bahl J; Marathe BM; Culhane M; Stigger-Rosser E; Darnell D; Kaplan BS; Lowe JF; Webby RJ; Govorkova EA
Antiviral Res; 2015 May; 117():10-9. PubMed ID: 25701593
[TBL] [Abstract][Full Text] [Related]
7. An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.
Hu Y; Musharrafieh R; Ma C; Zhang J; Smee DF; DeGrado WF; Wang J
Antiviral Res; 2017 Apr; 140():45-54. PubMed ID: 28087313
[TBL] [Abstract][Full Text] [Related]
8. Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate.
Shin JS; Ku KB; Jang Y; Yoon YS; Shin D; Kwon OS; Go YY; Kim SS; Bae MA; Kim M
J Microbiol; 2017 Dec; 55(12):979-983. PubMed ID: 29214495
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers.
Ma C; Zhang J; Wang J
Mol Pharmacol; 2016 Sep; 90(3):188-98. PubMed ID: 27385729
[TBL] [Abstract][Full Text] [Related]
10. M2 protein-a proton channel of influenza A virus.
Betakova T
Curr Pharm Des; 2007; 13(31):3231-5. PubMed ID: 18045172
[TBL] [Abstract][Full Text] [Related]
11. Reduction of Neuraminidase Activity Exacerbates Disease in 2009 Pandemic Influenza Virus-Infected Mice.
Ranadheera C; Hagan MW; Leung A; Collignon B; Cutts T; Theriault S; Embury-Hyatt C; Kobasa D
J Virol; 2016 Nov; 90(21):9931-9941. PubMed ID: 27558428
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses.
Chen HW; Cheng JX; Liu MT; King K; Peng JY; Zhang XQ; Wang CH; Shresta S; Schooley RT; Liu YT
Antiviral Res; 2013 Sep; 99(3):371-82. PubMed ID: 23820269
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis and treatment of influenza virus infection.
Kandel R; Hartshorn KL
BioDrugs; 2001; 15(5):303-23. PubMed ID: 11437694
[TBL] [Abstract][Full Text] [Related]
14. Coadministration of Hedera helix L. Extract Enabled Mice to Overcome Insufficient Protection against Influenza A/PR/8 Virus Infection under Suboptimal Treatment with Oseltamivir.
Hong EH; Song JH; Shim A; Lee BR; Kwon BE; Song HH; Kim YJ; Chang SY; Jeong HG; Kim JG; Seo SU; Kim H; Kwon Y; Ko HJ
PLoS One; 2015; 10(6):e0131089. PubMed ID: 26098681
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of synergistic inhibitory effects of neuraminidase inhibitors and methylglyoxal against influenza virus infection.
Charyasriwong S; Watanabe K; Rahmasari R; Matsunaga A; Haruyama T; Kobayashi N
Arch Med Res; 2015 Jan; 46(1):8-16. PubMed ID: 25523147
[TBL] [Abstract][Full Text] [Related]
16. Influenza A Virus Nucleoprotein: A Highly Conserved Multi-Functional Viral Protein as a Hot Antiviral Drug Target.
Hu Y; Sneyd H; Dekant R; Wang J
Curr Top Med Chem; 2017; 17(20):2271-2285. PubMed ID: 28240183
[TBL] [Abstract][Full Text] [Related]
17. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection.
Fukao K; Noshi T; Yamamoto A; Kitano M; Ando Y; Noda T; Baba K; Matsumoto K; Higuchi N; Ikeda M; Shishido T; Naito A
J Antimicrob Chemother; 2019 Mar; 74(3):654-662. PubMed ID: 30476172
[TBL] [Abstract][Full Text] [Related]
18. BPR2-D2 targeting viral ribonucleoprotein complex-associated function inhibits oseltamivir-resistant influenza viruses.
Shih SR; Horng JT; Poon LL; Chen TC; Yeh JY; Hsieh HP; Tseng SN; Chiang C; Li WL; Chao YS; Hsu JT
J Antimicrob Chemother; 2010 Jan; 65(1):63-71. PubMed ID: 19892833
[TBL] [Abstract][Full Text] [Related]
19. Design, in silico studies, synthesis and in vitro evaluation of oseltamivir derivatives as inhibitors of neuraminidase from influenza A virus H1N1.
Neri-Bazán RM; García-Machorro J; Méndez-Luna D; Tolentino-López LE; Martínez-Ramos F; Padilla-Martínez II; Aguilar-Faisal L; Soriano-Ursúa MA; Trujillo-Ferrara JG; Fragoso-Vázquez MJ; Barrón BL; Correa-Basurto J
Eur J Med Chem; 2017 Mar; 128():154-167. PubMed ID: 28182988
[TBL] [Abstract][Full Text] [Related]
20. Combination activity of neuraminidase inhibitor oseltamivir and α-tocopherol in influenza virus A (H3N2) infection in mice.
Galabov AS; Mileva M; Simeonova L; Gegova G
Antivir Chem Chemother; 2015 Aug; 24(3-4):83-91. PubMed ID: 27341844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
